ALSO NOTED: Most patients don't respond to breast cancer drug; Germans investigating Bayer for aspirin price-fixing;

> Most women with breast cancer don't respond to the common chemo drug Taxol, according to a new study from the University of Texas M.D. Anderson Cancer Center--but the 15 percent to 20 percent who have overactive HER-2 genes do, raising hopes of personalizing chemotherapy. Report

> German antitrust regulators searched the offices of Bayer for evidence that the drug maker has engaged in aspirin price-fixing. Report

> The FDA warned Medtronic against marketing its spinal treatment systems more broadly than their approved uses would allow. Report

> Pfizer is likely to get $6.7 million in tax breaks for a $50 million construction project near St. Louis. Report

> Glenmark Pharmaceuticals of India plans to raise $150 million on the financial markets, including a stock offering. Report

> The Street's Lenny Dykstra is bullish on Wyeth stock. Report

> Glaxo has agreed to pay Synta $80 million up front and up to $1.1 billion in total for the deal covering STA-4783, which has demonstrated efficacy in improving median survival rates for melanoma patients in a mid-stage study. Report

> Australia's Living Cell Technologies is garnering headlines with some intriguing responses tracked in a tiny diabetes trial undertaken in Russia. Report

And Finally… Can a pill take grief away? Doctors apparently think so; they're prescribing anti-anxiety meds to the bereaved at record rates--and some patients never stop taking them. Report